Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer

Jia, Shiyu; Zhang, Rui; Li, Ziyang; Li, Jinming

doi:10.18632/oncotarget.17184

Cited by 135 publications

(105 citation statements)

References 98 publications

(126 reference statements)

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…They have been widely used for early DM detection, monitoring prognoses and treatment efficacy, and risk stratification for some solid tumors [10,11] . The CellSearch system is the most widely used assay for CTCs, and depends on expression of CTC-surface epithelial cell adhesion molecule (EpCAM) [12].…”

Section: Introductionmentioning

confidence: 99%

Circulating Tumor Cells Correlate with Clinicopathological Features and Outcomes in Differentiated Thyroid Cancer

Qiu¹,

Wei²,

Sun³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: As biomarkers, circulating tumor cells (CTCs) from solid tumors can predict metastases and prognoses, and help monitor treatment efficacy. However, conventional CellSearch methods have low sensitivity to differentiated thyroid cancer (DTC) CTCs. In this study, for the first time, we used negative enriching (NE) immunofluorescence–in situ hybridization (iFISH) of chromosome 8 to capture and identify CTCs in DTC patients; and investigated how CTCs correlate with clinicopathological factors and prognosis in DTC patients with distant metastases (DM). Methods: In this prospective study, we enrolled 72 patients with DTC before they underwent ¹³¹I treatment, and 30 healthy controls (HC). Their CTCs were measured in 7.5 ml peripheral blood using the NE–iFISH technique. CTC was defined by the aneuploidy. Results: We detected CTCs in 62 (86.1%) of the 72 subjects with DTC. The mean number of CTCs in patients with DTC with DM (DM⁺) was significantly higher than in the HC group (P< 0.001) and DTC patients without DM (DM^-; P=0.0016). We found CTCs ≥ 5 was significantly associated with DM⁺ DTC (P=0.009; sensitivity: 64.3%; specificity: 83.8%); CTCs ≥ 7 was related to poor response to ¹³¹I treatment (sensitivity: 73.7 %; specificity: 69.6 %), and was also associated with worse prognosis in DM⁺ DTC (P< 0.001). Conclusion: We found CTCs ≥ 5 to be a potential predictive index for DM⁺ DTC; and CTCs ≥7 as a possible indicator of poor response to ¹³¹I treatment and worse prognosis in DM⁺ DTC.

show abstract

Section: Introductionmentioning

confidence: 99%

Circulating Tumor Cells Correlate with Clinicopathological Features and Outcomes in Differentiated Thyroid Cancer

Qiu¹,

Wei²,

Sun³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…CTCs are captured in a number of ways, including immune recognition, separation based on size or stiffness, and other chemical recognition methods. Once they are captured, though, CTCs can provide valuable insight into the dynamic fluctuations and characteristics of the disease without requiring access to the tumor site[27]. …”

Section: Liquid Biopsy Biomarkers and Biogenesismentioning

confidence: 99%

“…Exosomes are small, membrane-bound vesicles that are shed from cells for signaling and contain a number of biomolecules such as nucleic acids and proteins[27]–[30]. They tend to be in the tens to hundreds of nanometers in size, and have the advantage that their contents are protected from degradation within a lipid membrane[29].…”

Section: Liquid Biopsy Biomarkers and Biogenesismentioning

confidence: 99%

“…Because of similarities between the exosome membrane and CTC membranes they can be isolated using the same immune recognition. Other methods of separation include, but are not limited to, size differentiation and ultracentrifugation procedures [27], [31]–[33]. Exosomes circulate in the blood in concentrations above 10 9 individual exosomes per milliliter of blood and the total quantity scales with the severity of the tumor[27], [34].…”

Section: Liquid Biopsy Biomarkers and Biogenesismentioning

confidence: 99%

See 1 more Smart Citation

Advances in liquid biopsy on-chip for cancer management: Technologies, biomarkers, and clinical analysis

Tadimety

Closson

et al. 2018

Critical Reviews in Clinical Laboratory Sciences

View full text Add to dashboard Cite

Liquid biopsy, as a minimally invasive method of gleaning insight into the dynamics of diseases through a patient fluid sample, has been growing in popularity for cancer diagnosis, prognosis, and monitoring. While many technologies have been developed and validated in research laboratories, there has also been a push to expand these technologies into other clinical settings and as point of-care devices. In this review we discuss and evaluate microchip-based technologies for circulating tumor cell (CTC), exosome, and circulating tumor nucleic acid (ctNA) capture, detection, and analysis. Such integrated systems streamline otherwise multiple-step, manual operations to get a sample-to-answer quantitation. In addition, analysis of disease biomarkers is suited to point of care settings because of ease of use, low consumption of sample and reagents, and high throughput. We also cover the basics of biomarkers and their detection in biological fluid samples suitable for liquid biopsy on-chip. We focus on emerging technologies that process a small patient sample with high spatial-temporal resolution and derive clinically meaningful results through on-chip biomarker sensing and downstream molecular analysis in a simple workflow. This critical review is meant as a resource for those interested in developing technologies for capture, detection, and analysis platforms for liquid biopsy in a variety of settings.

show abstract

“…Importantly, CTC could be used to generate CTC‐derived explants (CDX) that show broad similarity with the primary tumor; hence, the response of CDX to therapeutic agents mirrors the patient's response to the same treatment . The major demerit of CTC is that there are only low‐input amounts of CTC from the bloodstream that could be isolated using limited capture techniques . Exosomes are small membrane vesicles released from diverse cell types that transfer functional molecules such as DNA, miRNA, proteins and lipid to the recipient cells .…”

Section: Genome‐based Medicine That Leads To Cancer Precision Medicinementioning

confidence: 99%

Breast cancer: The translation of big genomic data to cancer precision medicine

2017

View full text Add to dashboard Cite

Cancer is a complex genetic disease that develops from the accumulation of genomic alterations in which germline variations predispose individuals to cancer and somatic alterations initiate and trigger the progression of cancer. For the past 2 decades, genomic research has advanced remarkably, evolving from single‐gene to whole‐genome screening by using genome‐wide association study and next‐generation sequencing that contributes to big genomic data. International collaborative efforts have contributed to curating these data to identify clinically significant alterations that could be used in clinical settings. Focusing on breast cancer, the present review summarizes the identification of genomic alterations with high‐throughput screening as well as the use of genomic information in clinical trials that match cancer patients to therapies, which further leads to cancer precision medicine. Furthermore, cancer screening and monitoring were enhanced greatly by the use of liquid biopsies. With the growing data complexity and size, there is much anticipation in exploiting deep machine learning and artificial intelligence to curate integrative “−omics” data to refine the current medical practice to be applied in the near future.

show abstract

Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer

Cited by 135 publications

References 98 publications

Circulating Tumor Cells Correlate with Clinicopathological Features and Outcomes in Differentiated Thyroid Cancer

Circulating Tumor Cells Correlate with Clinicopathological Features and Outcomes in Differentiated Thyroid Cancer

Advances in liquid biopsy on-chip for cancer management: Technologies, biomarkers, and clinical analysis

Breast cancer: The translation of big genomic data to cancer precision medicine

Contact Info

Product

Resources

About